Nantkwest Inc CS (NK) Stock News

USA - NASDAQ:NK -

32.49

+4.21 (+14.89%)

Last: 3/9/2021, 8:00:01 PM

32.08

-0.41 (-1.26%)

After Hours: 3/9/2021, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NK Latest News, Press Relases and Analysis

All

Press Releases

3 months ago - By: Benzinga - Mentions: IGC SPY PRGS BA ...

US Stocks Likely To Open Higher, Continuing Record-Setting Advances: June Has Never Seen An All-Time High Since 1950, Highlights Expert

4 years ago - By: Haeggquist & Eck, LLP

Haeggquist & Eck, LLP Announces Investigation Regarding Whether PennyMac Required Home Owners to Purchase Excess Homeowners’ Insurance for Home Loans and Home Loan Refinancing

5 years ago - By: Benzinga - Mentions: XNET ELDN APT NEX ...

82 Biggest Movers From Yesterday

5 years ago - By: NantKwest, Inc.

ImmunityBio and NantKwest Complete Merger

5 years ago - By: NantKwest, Inc.

Stockholders of NantKwest Approve Merger With ImmunityBio

5 years ago - By: NantKwest, Inc.

ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Africa, Oral and Sublingual in the U.S.

5 years ago - By: NantKwest, Inc.

All Three Independent Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Recommend NantKwest Stockholders Vote “FOR” the Pending Merger With ImmunityBio

5 years ago - By: ImmunityBio, Inc.

ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors

5 years ago - By: ImmunityBio, Inc.

ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate

5 years ago - By: Bloomberg

ImmunityBio Covid-19 Vaccine to Be Trialed in South Africa

5 years ago - By: Lifshitz Law Firm, P.C. - Mentions: FFG CATM VIE

Lifshitz Law Firm, P.C. Announces Investigation of CATM, FFG, NK, and VIE

5 years ago - By: NantKwest, Inc.

ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity